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Abstract
Purpose An herbal preparation, STW 5, used clinically in
functional dyspepsia and irritable bowel syndrome, has been
shown to possess properties that may render it useful in
inflammatory bowel disease (IBD). The present work was
conducted to study its effectiveness in a rat model of IBD.
Methods An experimental model reflecting ulcerative colitis
in man was adopted, whereby colitis was induced in Wistar
rats by feeding them 5 % dextran sulfate sodium (DSS) in
drinking water for one week. STW 5 and sulfasalazine (as a
reference standard) were administered orally daily for
1 week before colitis induction and continued during DSS
feeding. The animals were then sacrificed, and the severity
of colitis was evaluated macroscopically and microscopical-
ly. Colon samples were homogenized for determination of
reduced glutathione, tumor necrosis factor-α, and cytokine-
induced neutrophil chemoattractant-3 as well as myeloper-
oxidase, glutathione peroxidase, and superoxide dismutase.
In addition, colon segments were suspended in an organ
bath to test their reactivity towards carbachol, KCl, and
trypsin.
Results STW 5 and sulfasalazine were both effective in
preventing the shortening of colon length and the increase
in both colon mass index and total histology score as well as
the changes in biochemical parameters measured except
changes in dismutase activity. DSS-induced colitis led to
marked depression in colonic responsiveness to the agents
tested ex vivo, an effect which was normalized by both
drugs.
Conclusions The findings point to a potential usefulness of
STW 5 in the clinical setting of ulcerative colitis.
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Introduction
Inflammatory bowel disease (IBD) in man is usually man-
ifested either as ulcerative colitis (UC) or as Crohn's disease.
In both conditions, the inflammatory processes in the gut are
associated with disturbances in gastrointestinal motility [1,
2]. One animal model of UC involves feeding dextran
sulfate sodium (DSS) in drinking water to rodents [3, 4].
The model is widely used for screening purposes because of
its ease of induction, reproducibility, well-characterized mu-
cosal injury [3], and its responsiveness to effective agents
such as sulfasalazine. The aims of management of IBD are
the induction and maintenance of remission. However, no
maintenance medication has been shown to be completely
effective for preventing relapse. The search, therefore, con-
tinues in the hope of finding effective and relatively non-
toxic agents that could be useful in prolonging remission
intervals while minimizing adverse reactions.
STW 5 consists of a fixed dose combination of well-
characterized and standardized nine herbal extracts, namely
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bitter candytuft (Iberis amara), melissa leaf (Melissa officina-
lis), chamomile flower (Matricaria recutita), caraway fruit
(Carum carvi), peppermint leaf (Mentha piperita), Angelica
root (Angelica archangelica), milk thistle (Silybum marianum),
greater celandine herb (Chelidonium majus) and liquorice root
(Glycyrrhiza glabra) that has proved to be effective against
functional gastrointestinal disorders such as functional dyspep-
sia and irritable bowel syndrome [5–7]. Khayyal et al. [8, 9]
reported on its anti-ulcerogenic and mucosal protective effects
and related at least part of its usefulness to its anti-inflammatory
properties, a fact that prompted us to further explore the poten-
tial benefits of the drug in the DSS model of IBD.
Materials and methods
Drugs
STW 5 was provided in the form of its commercial prepa-
ration (Iberogast®) by Steigerwald Arzneimittelwerk GmbH,
Darmstadt, Germany. The preparation is provided as a tinc-
ture containing 31 % alcohol. Sulfasalazine was obtained
from El-Kahira Pharmaceutical Company, Cairo, Egypt and
was used as a suspension in 1 % methylcellulose. The
concentration of all drugs was adjusted so that the required
dose per 200 g of rat was found in 1 mL of solution/
suspension.
Animals
Adult male Wistar rats, weighing 150–200 g each, were
obtained from the Modern Veterinary Office for Laboratory
Animals, Cairo, Egypt and were left to acclimatize for
1 week before subjecting them to experimentation. They
were provided with a standard pellet diet and were given
water ad libitum. The animals were kept at a temperature of
22±3°C and a 12-h light/dark cycle as well as a constant
relative humidity throughout the experimental period. The
study was approved by the Ethical Committee for Animal
Experimentation at the Faculty of Pharmacy, Cairo University,
Cairo, Egypt.
Induction of colitis
Colitis was induced by adding 5 % DSS (molecular weight
of 37–40 kD; TdB Consultancy, Uppsala, Sweden) to the
drinking water, ad libitum for 7 days [3, 4].
Experimental design
Two sets of experiments were carried out: one with a view to
determine changes in histological and biochemical parame-
ters and one to study motility changes ex vivo.
Study of effect of STW 5 on histological and biochemical
parameters
Rats were randomly assigned to seven groups of ten animals
each as follows: two control groups given 31 % ethanol
(vehicle of STW 5), four STW 5-treated groups (0.5, 1, 2,
and 5 mL/kg), and one sulfasalazine-treated group (300 mg/
kg). The drugs were administered orally once per day for
1 week while keeping the animals on a normal pellet diet
and water ad libitum. DSS (5 %) was then added to the
drinking water of all groups except one of the control groups
(considered as normal control, not receiving DSS). DSS treat-
ment was continued for 1 week while keeping the rats under
the same drug regimen during that time. Animals were
weighed just before DSS treatment and just before autopsy
to determine whether colitis had an effect on body weight.
Twenty-four hours after the last dose of treatment, the
rats were sacrificed by cervical dislocation. The colon was
excised and its length measured. The colon was opened
longitudinally, rinsed in ice-cold normal saline, cleaned of
fat and mesentery, blotted on filter paper, and weighed. The
ratio of colon weight in milligrams to total body weight in
grams was taken as the colon mass index and was used as a
measure of the degree of colonic edema and severity of
inflammation. The colon was then cut longitudinally into
two parts. One specimen was fixed in 10 % formalin and
preserved for histological examination, and the other was
homogenized in ice-cold normal saline to obtain a 10 %
homogenate for assessment of the chosen biochemical
parameters.
Determination of biochemical parameters The colon
homogenate was divided into four aliquots for determining
the following parameters:
Reduced glutathione One aliquot was deproteinized with ice-
cold 5 % sulfosalicylic acid then centrifuged at 3,000 rpm for
20 min. The supernatant was used for spectrophotometric
estimation of glutathione (GSH) [10].
Myeloperoxidase activity An aliquot was mixed with an
equal volume of 100 mmol/L phosphate buffer pH 6 con-
taining 1 % hexadecyltrimethylammonium bromide. The
mixture was freeze-thawed, sonicated for 10 s and centri-
fuged at 10,000 rpm for 15 min at 4°C. The supernatant was
used for spectrophotometric estimation of myeloperoxidase
(MPO) activity [11].
Tumor necrosis factor alpha and cytokine-induced neutro-
phil chemoattractant-3 An aliquot was centrifuged at 13
000 rpm for 30 minutes at 4°C. The supernatant was used
for assaying tumor necrosis factor (TNF)-α and cytokine-
induced neutrophil chemoattractant (CINC)-3 using specific
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enzyme-linked immunosorbent assay kits (R&D Systems
GmbH, Wiesbaden, Germany).
Superoxide dismutase and glutathione peroxidase An
aliquot was ultra-centrifuged at 105 000 g for 15 minutes
at 4°C. The supernatant was used for the assay of superoxide
dismutase (SOD) and glutathione peroxidase (GPx) using
specific spectrophotometric kits (Biodiagnostic, Giza, Egypt).
Histopathological examination Transverse sections, 4-6 μm
in size, were prepared from paraffin-embedded colon seg-
ments from each animal of all experimental groups except
those treated with the two lower doses of STW 5. The sections
were stained with hematoxylin and eosin (H&E) and exam-
ined under a light microscope. They were graded individually
by a pathologist blinded to the treatment regimen. Each sec-
tion was assigned a damage score between 0 and 3 for each of
five parameters, namely, necrosis of epithelium, inflammatory
infiltrate in lamina propria, inflammatory infiltrate in submu-
cosa, dilatation of crypts, and submucosal edema.
The scores for the five parameters measured for each rat
were summed to obtain the “total histology score,” being
maximally 15 (three being themaximum for the five parameters
examined). The data were then represented using a box plot.
Colonic responsiveness ex vivo
Rats were allocated to four groups of animals, each com-
prising six rats: two control groups, one group treated with
sulfasalazine (300 mg/kg) and one group with STW 5
(5 mL/kg). They were subjected to the same treatment
procedure as above.
After sacrifice, segments of the colon approximately
20 mm in length were taken 3 cm from the anal orifice
and suspended longitudinally under a 1-g load in a 30-mL
water jacketed organ bath containing Krebs-Henseleit
solution of the following composition (millimole per liter):
NaCl, 119.0; KCl, 4.7; CaCl2, 2.5; MgSO4, 1.2; KH2PO4,
1.2; NaHCO3, 25.0; glucose, 5.5. The bath was maintained
at 37°C and aerated with carbogen.
The preparation was allowed to equilibrate for 1 h. Isotonic
contractions were recorded for carbachol (0.03–1 μmol/L)
and KCl (9.09–72.7 mmol/L). The relaxant effect of a
protease-activated receptor (PAR)-2 agonist, trypsin (MP
Biomedicals Inc., Solon, USA) was evaluated on a muscle
strip pre-contracted with a submaximal dose of carbachol.
Trypsin (30 μmol/L) was applied 5 min after the addition of
carbachol and the extent of relaxation measured.
Statistical analysis
SPSS 17.0 was used for data management and data analysis.
Mean and standard error described continuous variables
with median and range for discrete data. Parametric and
non-parametric ANOVA compared means and medians of
different study groups. When significant, pair-wise compar-
isons were done using most restrictive tests: Scheffe test. P
value was considered significant at 0.05 or less.
Fig 1 Effect of pretreatment with STW 5 on the increase in body
weight of animals with DSS-induced colitis measured from the time of
induction of colitis until sacrifice. Data are expressed as means±SEM
of at least eight animals. #P≤0.05 vs. normal control
Fig. 2 Effect of STW 5 on colon length (a) and colon mass index (b)
in rats with DSS-induced colitis. Data are expressed as means±SEM of
at least eight animals. #P≤0.05 vs. normal control, @P≤0.05 vs. DSS
control
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Results
Body weight
DSS-induced colitis led to a dramatic inhibition in the rate
of weight gain of rats by ca. 70 % (p<0.001). Pretreatment
with STW 5 (2 and 5 mL/kg) tended to restore the normal
rate of weight gain (p00.09) while the lower doses of STW
5 and sulfasalazine (300 mg/kg) had little effect (Fig. 1).
Colon length and colon mass index
Induction of colitis led to a reduction in colon length by
17 % as compared to the normal control group (Fig. 2a).
This was associated with a 35 % increase in colon mass
index (Fig. 2b). Pretreatment with STW 5 tended to prevent
these changes in a dose-dependent manner. The effect of the
two higher doses of STW 5 was comparable to that of
sulfasalazine (Fig. 2; p<0.001 and p00.002 for colon length
and colon mass index respectively).
Fig. 3 Effect of STW 5 on reduced glutathione (GSH) levels (a),
glutathione peroxidase (GPx) activity (b) and superoxide dismutase
(SOD) activity (c) in colonic tissue of rats with DSS-induced colitis.
Data are expressed as means±SEM of at least eight animals. #P≤0.05
vs. normal control, @P≤0.05 vs. DSS control
Fig. 4 Effect of STW 5 on inflammatory parameters in colonic tissue
of rats with DSS-induced colitis. aMyeloperoxidase (MPO) activity, b
TNF-α levels, c CINC-3 levels. Data are expressed as means ± SEM of
at least eight animals. #P≤0.05 vs. normal control, @P≤0.05 vs. DSS
control
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Biochemical parameters
The induction of colitis was associated with changes in the
various parameters indicative of oxidative stress. This was
evidenced by a marked reduction in colonic content of GSH
(Fig. 3a) as well as the activities of GPx (Fig. 3b) and SOD
(Fig. 3c). Pretreatment with STW 5 dose-dependently re-
versed the deranged levels of GSH and GPx (Fig. 3a and b,
respectively; p<0.001). The reduction in colonic SOD activity
induced by DSS was largely prevented by pretreatment with
either STW 5 or sulfasalazine (Fig. 3c).
DSS-induced colitis led to a significant increase in MPO
activity in the colon, an effect which was largely prevented
by pretreatment with either STW 5 or sulfasalazine (Fig. 4a;
p<0.001).
The inflammatory mediators, TNF-α and CINC-3
(Fig. 4b and c, respectively), were elevated in colonic tissue
of DSS treated rats, but the rise was prevented by pretreat-
ment with either STW 5 or sulfasalazine (p<0.001).
Histopathological examination
The major elements of colonic inflammation include crypt
destruction, mucosal ulceration, and infiltration of lympho-
cytes into the mucosal tissue. Representative histological
images of H&E-stained colon sections from each group
are shown in Fig. 5. In contrast to normal control animals
(Fig. 5a), DSS-treated animals (Fig. 5b) showed marked
necrosis of the epithelium, intraluminal accumulation of
mucous exudates, dilatation of the crypts, and submucosal
edema. These changes were associated with massive inflam-
matory cell infiltration in the lamina propria and submucosa.
The infiltrated inflammatory cells included polymorphonuclear
leucocytes, lymphocytes, and plasma cells.
Fig. 5 Effect of STW 5 on
histopathological changes of rat
colon in DSS model of colitis.
a Normal control rat: normal
histological structure of
mucosa, b DSS control rat
showing necrosis of epithelium,
distortion of crypts, inflammatory
infiltrate in lamina propria
and submucosa as well as
submucosal oedema, c
sulfasalazine pre-treated rat
showing nearly normal structure,
d STW5 (2mL/kg) pretreated rat
showing moderate inflammatory
infiltrate in lamina propria and
submucosa, e rat pre-treated
with STW 5 (5 mL/kg)
showing minimal changes.
(H&E staining, ×200 original
magnification). f Total histology
score, data are expressed as box
plots of the median of at least
eight animals. #P≤0.05 vs.
normal control, @P≤0.05 vs.
DSS control
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The total histology score was markedly increased in
DSS-treated rats (Fig. 5f). Pretreatment with STW 5 largely
protected against the histological changes induced by DSS
as evidenced by the lesser severity of the above parameters.
The inflammatory infiltration in the lamina propria and
submucosa was only mild to moderate (Fig. 5d, e), and the
total histology score was markedly decreased (Fig. 5f). The
higher the dose of the drug, the greater was its protective
effect. The effect of STW 5 was similar to a large extent to
the effects of sulfasalazine (Fig. 5c, f).
Colonic motility
Colonic strips from rats with colitis showed depressed re-
sponsiveness to carbachol and KCl, an effect which tended
to be prevented by both STW 5 and sulfasalazine (Fig. 6a, b,
respectively).
Trypsin (30 μmol/L) was found to cause a 64 % relaxation
of the carbachol-induced contraction of the normal rat colon.
The extent of relaxation was markedly reduced in colons of rats
with DSS-induced colitis, reaching only 24 %. Pretreatment
with either sulfasalazine or STW5 tended to restore the relaxing
effect of trypsin to reach 58 % and 39 %, respectively (Fig. 6c).
Discussion
The effect of STW 5 on various parameters that have
been deranged as a result of inducing colitis through the
administration of DSS in rats was studied. Macroscopically,
DSS-induced colitis resulted in a marked reduction in the
rate of growth of the animals. This feature of DSS colitis
resembles the common problem of weight loss observed in
IBD patients [12–14]. STW 5 in the higher dose range as
well as sulfasalazine tended to restore the rate of weight
gain. The effects on weight gain correlated well with the
changes in colon length and colon mass index. The DSS-
induced increase in colon mass index may be related to the
submucosal edema shown histologically while the colon
shortening may be associated with its thickening due to
edema and infiltration of inflammatory cells into the lamina
propria and submucosa [15, 16]. STW 5 led to marked
reduction in the inflammatory infiltrate in both lamina prop-
ria and submucosa and dose-dependently protected against
changes in colon length and mass index.
Neutrophil infiltration is usually associated with in-
creased MPO activity, a parameter which correlates well
with the severity of the lesions in acute DSS-induced colitis
[17]. MPO itself possesses cytokine-like properties and can
activate neutrophils [18] resulting in the release of a wide
range of inflammatory mediators and reactive oxygen spe-
cies. A decrease in MPO activity after pretreatment with
STW 5 is therefore indicative of a reduction in neutrophil
infiltration and reduction of the inflammatory process. Sim-
ilar effects were recently reported in a model of reflux
esophagitis [19].
The increased level of oxidative stress in the present
study was associated with marked depletion of the cellular
antioxidant, GSH as was reported in earlier studies [20, 21].
Other related parameters, such as the activities of the two
antioxidant enzymes, SOD and GPx were also decreased.
Such effects have also been reported in IBD patients [22].
Pretreatment with STW 5 protected dose dependently
against the rise in free radical production by DSS, evidenced
Fig. 6 Effect of STW 5 on the colonic motility changes induced by
DSS. a Non-cumulative concentration–response curves to carbachol, b
non-cumulative concentration-response curves to KCl, c relaxant effect
of trypsin after pre-contraction with carbachol [trypsin (30 μmol/L)
was applied 5 min after addition of submaximal dose of carbachol].
Data are expressed as means ± SEM of at least four animals. # P≤0.05
vs. normal control, @P≤0.05 vs. DSS control
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by restoration of colonic GSH, SOD, and GPx levels. Earlier
authors reported that STW 5 possesses potent antioxidant
activity in several in vitro models by virtue of its radical-
scavenging activity and its ability to specifically inhibit
metabolic pathways leading to cellular release of free
radicals [23, 24].
Other factors that may be involved in the inflammatory
process in human IBD as well as in DSS colitis include pro-
inflammatory cytokines such as interleukin (IL)-1β and
TNF-α [25–27]. Both TNF-α and IL-1β have been impli-
cated in stimulating the production of IL-8 [28], a chemo-
kine implicated in the pathophysiology of IBD [29]. One of
the functional analogues of IL-8 in rodents is CINC-3, a
potent chemotactic factor for neutrophils. The levels of
TNF-α and CINC-3 were significantly raised in the colon
following induction of colitis by DSS. Pretreatment with
STW 5 dose dependently prevented the rise in both TNF-
α and CINC-3. The reduction in TNF-α levels by STW 5,
which was also described in several other models of GI
inflammation [8, 9, 19, 30], may be explained partly by
the previously reported inhibition of the translocation of
nuclear factor-kappa B (NF-κB) [31]. NF-κB is believed
to play a major role in the regulation of pro-inflammatory
gene transcription [32].
Colitis is often associated with bowel motility changes
leading to either constipation or diarrhea in patients with
IBD [33, 34]. Colonic contractility has been reported to be
deranged also in animal models of colitis [35] and to persist
even after resolution of inflammation [36]. Both receptor-
dependent and -independent mechanisms contribute to the
altered smooth muscle function during colitis [37]. Colonic
tissue from rats with DSS-induced colitis exhibited reduced
contractility to both a receptor-dependent muscarinic ago-
nist, carbachol, and a receptor-independent one, KCl, which
stimulates smooth muscle directly by depolarizing the intact
cell membranes.
The findings are suggestive of a reduced responsiveness
of the colon to both parasympathetic stimulation and to
direct muscle stimulation by depolarizing agents. Although
the myogenic mechanism for decreased motility of inflamed
intestinal tissue have not been well examined, some reports
suggest that it involves a decreased activity of voltage-
dependent L-type Ca2+ channels [38, 39], an effect that
has been shown to be reversed by NF-κB inhibitors [39].
Since STW 5 was shown to inhibit the translocation and
hence activation of NF-κB [31] the observed effects of the
drug on restoring normal colonic responsiveness may be due
to its anti-inflammatory effect, and hence conservation of
L-type Ca2+ channel activity.
On parallel lines, Michael et al. [30] reported that in vitro
induction of inflammation in the jejunum and small intestine
by intraluminal instillation of TNBS led to a decreased re-
sponse to acetylcholine, but the response was restored when
STW 5was instilled concurrently, thereby reducing histopath-
ological inflammatory changes in the mucosa. Earlier studies
had shown that STW 5 increased the tone of intestinal or
colonic preparations, but had an antispasmodic action when
tested against acetylcholine or histamine induced contractions
[40], suggesting that STW 5 by virtue of one or more of its
components may interact with the muscarinic and/or hista-
minergic receptors. Studies by Simmen et al. [41] in vitro
showed that STW 5 indeed can bind to muscarinic M3 recep-
tors in the intestine as well as to some serotonergic receptors.
The modulatory effect of STW 5 may therefore be partially
related to up- or downregulation of respective receptors.
As intestinal inflammation is associatedwith the generation
and release of proteases that are potential activators of PAR-2,
a receptor known to modulate intestinal motility, identifying
the role of PAR-2 in the present model was of interest. Trypsin
was found to inhibit carbachol-induced contractions of the
normal rat colon. After colonic inflammation induced by
DSS, the inhibitory effect of trypsin on carbachol-induced
contractions was suppressed. However, pretreatment with
STW 5 showed only a tendency to reduce the effect of trypsin.
In conclusion, the present findings show that STW 5
prevents both the colonic inflammatory changes and the
motility disturbances in the DSS model of rat colitis. Res-
toration of normal responsiveness is probably related, at
least in part, to the anti-inflammatory properties of the drug.
If the present findings can be confirmed in a clinical setting,
STW 5 may possibly have some therapeutic usefulness in
the management of human IBD. It could be used as an add-on
to standard medication to help maintain remission and ame-
liorate motility disturbances experienced by IBD patients.
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